



Market Snapshot

NASDAQ ticker symbol	SRTS
Stock price (07/01/19)	\$5.65
52-week range	\$4.75- \$9.23
Market capitalization	\$93 mil
Shares outstanding	16.5 mil
Institutional ownership	8.4%
Insider ownership	32.9%
Fiscal year-end	Dec 31

ABOUT SENSUS HEALTHCARE

Sensus Healthcare, Inc. is a medical device company specializing in cost-effective non-invasive and minimally-invasive treatments for certain oncology and dermatology conditions. Sensus offers the SRT-100™, SRT-100+™ and SRT-100 Vision™ systems to treat non-melanoma skin cancers (NMSC) and keloids. These systems incorporate a proprietary low-energy x-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development. Sensus also offers the Sculptura™ robotic radiation oncology system, which provides single-dose, targeted intraoperative triple-modulated radiotherapy (IORT) and brachytherapy utilizing proprietary, state-of-the-art 3D Beam Sculpting™ directly to the tumor site during surgery. With a portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

INVESTMENT HIGHLIGHTS

Safe, effective, patented and reimbursed products with patient, physician and payer benefits. NMSC patients have excellent clinical outcomes, no downtime and superior aesthetics with SRT vs. Mohs surgery. SRT physicians expand their practices and improve efficiencies, while increased patient visits heighten the opportunity for cross-selling treatments; equipment cost is recovered in as little as 6-9 months. Payers benefit from reimbursement comparable to Mohs, without the extra expenses for wound care and reconstructive surgery.

Clearly-defined customer base to treat a rapidly-growing patient population. The primary customers for SRT systems are dermatologists and plastic surgeons, with radiation oncologists representing an additional market opportunity. It is projected that there will be more than 6 million new cases of skin cancer per year by 2020, and the number of NMSC cases is already three times all other cancers combined.

Large U.S. market with OUS and pipeline opportunities. In the U.S. there are approximately 1,000 Mohs surgeons, 14,000 dermatologists, 6,500 plastic surgeons and 5,500 radiation oncologists. Sensus operates a direct salesforce in the U.S., with distributors in China and other countries outside the U.S. All SRT systems have regulatory clearance in the U.S., and the SRT-100 is cleared in Canada, China, the European Union, Israel, Mexico and Russia, with expectations for additional clearances in Latin American and Asian countries. Sensus plans to broaden SRT treatment indications to include psoriasis and other skin conditions.

Introduced Sculptura™, Modulated Robotic Brachytherapy - Intra-Operative Radiotherapy (M-IORT) System for breast and other surgically treated cancers with a dedicated oncology sales force. The addressable market for Sculptura is almost 7,000 sites in the U.S.

Strong financial momentum. Sensus recorded 28% revenue growth in 2018 to \$26.4 million with a 64% gross margin. The revenue model includes capital equipment sales plus an annual service contract. This model without significant consumables aligns with the evolving reimbursement environment. The balance sheet as of Dec. 31, 2018 had cash/equivalents of \$15.4 million and no debt.

Executive team has strong record with capital equipment business models. Led by industry veteran CEO Joseph Sardano, the executive team's experience includes capital equipment sales at GE, Siemens, Toshiba, Hologic and others.

THE FASTEST-GROWING & MOST-PREVALENT CANCER: NON-MELANOMA SKIN CANCER


Mohs (Surgical) Treatment Option

- Invasive and complicated procedure that requires a highly-skilled surgeon
- Often results in poor cosmetic outcomes in facial areas, forcing patients to consider reconstructive surgery and wound care
- Preexisting conditions (i.e., diabetes, heart conditions) increase the risk of poor healing outcomes
- Lower limb (e.g., shin) and scalp are especially hard-to-heal areas
- Quality-of-life is adversely impacted, especially during the recovery period



SRT (Non-Surgical) Treatment Option

- Comparable cure rates to Mohs, as supported by published clinical studies
- Non-invasive procedure with no lifestyle impact
- No anesthesia, no cutting and no pain
- No comorbidity limitations to patient selection
- Ideal to treat challenging sites on the body (e.g., lower limb, scalp)
- Multiple patient visits (10-20) allow the practice to cross-sell products and procedures
- Lower healthcare system costs compared with Mohs surgery



KELOIDS: A POTENTIALLY LARGER MARKET THAN NMSC

- Keloids are an area of irregular fibrous tissue formed at the site of a scar or injury
- The NIH estimates that 11+ million people worldwide are living with keloid scars
- Genetic predisposition to keloids among those of African, Latin and Asian descent
- In 2017 Sensus received keloid clearance in China
- Current treatment methods may reduce the size of the keloid but are not a permanent solution, and most patients are informed by their physicians “*there is no remedy*”
- Recurrence rates of keloids are very high, at up to 90%, and keloids frequently come back worse post-keloidectomy
- Insurance does not cover keloid removal unless it is combined with SRT
- Recent clinical study on keloid surgery followed by SRT had 3% recurrence
- Over 100 Sensus customer sites are treating keloids



SAFE & PROVEN TECHNOLOGY

Superficial Radiotherapy (SRT)

- Low-energy photo radiotherapy
- 100% of the energy is focused directly onto the surface of the skin using custom applicators
- Penetrates no deeper than 5mm below the surface of the skin
- Covered by IP portfolio
- Compact 30" x 30" footprint
- 2 models: SRT-100™ and SRT-100 Vision™
- Proven, award-winning technology
- Scalable platform for new, future indications




SRT-100 Vision™

SRT-100 Vision

- State-of-the art, image-guided SRT
- The world's first hybrid image-guided SRT platform (IGSRT)
- Designed to track disease progression, plan treatment, guide therapy, administer radiation and evaluate treatment
- Targets teaching hospitals and radiation oncology centers
- Comprehensive enterprise integration
- Advanced workflow and safety

Sculptura



- State-of-the-art 3D beam sculpting to precisely focus x-ray to treatment area
- Morpheus x-ray source for fast dose delivery rates
- Robotically assisted therapy system for ease of beam positioning/targeting
- Respiratory motion tracking for enhanced patient safety, treatment accuracy
- Single, targeted dose of radiation; no need for course of radiation treatments
- Patented proprietary technology
- Recurring consumables revenue
- Established reimbursement; provides savings to the healthcare system
- Strategic rollout to university hospital centers to support clinical studies for marketing and to provide wider validation – UPenn, Rabin Medical Center

GROWTH STRATEGY

- Expand U.S. operations, sales and marketing; leverage new contract with Premier and its 4,000+ hospital members
- Expand international markets particularly Latin America and Asia
- Add indications including psoriasis
- Increase awareness of SRT for treating keloids
- Rollout of M-IORT for breast and other cancers; starting with premier centers to support expanded indications

INVESTOR RELATIONS CONTACTS

Sensus Healthcare
Arthur Levine
ALevine@sensushealthcare.com
(800) 324-9890
www.sensushealthcare.com

LHA
Kim Sutton Golodetz
kgolodetz@lhai.com
(212) 838-3777
www.lhai.com

LHA
Bruce Voss
bvoss@lhai.com
(310) 691-7100
www.lhai.com